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The cardioprotective effect of amkdtplne, a long- 
acting dlhydropyridine derivative, was studied in 2 
experimental modefs of ischemia and reperfusion. 
Isolated and blood-perfused feline hearts were 
made gtobatty tschemlc for 60 minutes and then re- 
perfused for 60 minutes. Alterations of left ventric- 
ular developed pressure and compliance were moni- 
tored in both amtodipine-treated hearts and sallne- 
treated control animals. Changes in perfusion 
pressure indicated that amlodipine significantly re- 
duced myocardial oxygen consumption and coro- 
nary vascular resistance. Furthermore, a progres- 
slve Increase In resting left ventricular diastolic 
pressure indicated that amtodipine, administered 
before the onset of global ischemia, attenuated the 
development of ischemic contracture. Return of 
contractile fun&on 60 minutes after reperfusion 
and maintenance of tissue concentrations of efec- 
trolytes were significantly better In the amlodipine- 
treated group than in the control animals. 
In Intact canine hearts, regional myocardlal 
ischemia was induced for 90 minutes, followed by 
6 hours of reperfusfon. Although the hemodynamic 
variables and the size of the region of risk did not 
dlffer signfficantly between treated animals and 
control animals, the infarct sixe was significantly 
smatter in the amlodtpine-treated group than in the 
control animals, and a gradual reduction in coro- 
nary blood flow was observed in the control group 
that was prevented in the amlodipine group. A 
comparison of these findings with those observed 
with oxygen radical scavengers also is dlscussed. 
A detalkd report of these studies was published 
in The American Journal of Cardio/ogy 
(1969;64:1011-116l).Th& revlewlsfncludedhere 
to maintain continuity of the symposium for the 
convenience of the reader. 
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A mlodipine is a dihydropyridine calcium antago- nist shown to have a gradual onset and a sustained duration of action.’ -3 Because of the selectivity of 
the dihydropyridines for vascular smooth muscle and 
their lack of significant cardiac side effects,4*5 they may 
have the potential to limit myocardial injury during isch- 
emia and reperfusion.6 x 
Myocardial &hernia is associated with impaired cal- 
cium homeostasis.‘-‘I Ischemic tissue injury causes an 
increaset2-I4 in free intracellular calcium that leads to 
diminished recovery of myocardial contractile function, 
compromised membrane integrity and decreasing re- 
serves of cellular adenosine triphosphate. Inasmuch as 
the short-acting calcium antagonists diltiazem and nifed- 
ipine have been shown to protect the myocardium from 
irreversible tissue injury after global or regional ischemia 
followed by reperfusion,i5-i7 we assessed the potential for 
additional cardioprotective effects of a calcium antago- 
nist with a prolonged duration of action, amlodipine, in 2 
experimental models. The isolated and blood-perfused 
feline heart provided an experimental model for the in- 
duction of global myocardial ischemia18 and was used to 
ascertain the effects of amlodipine on mechanical and 
biochemical function after global ischemia and reperfu- 
sion. The intact canine heart provided a model for region- 
al myocardial ischemia followed by reperfusion.‘9J’ In 
this review, we summarize our previously reported experi- 
mental work with these 2 modelq2’ followed by a discus- 
sion of the potential usefulness of amlodipine and its 
mechanisms of action in myocardial ischemia and reper- 
fusion syndromes. We also compared these findings with 
those observed with oxygen radical scavenging agents. 
EXPERIMENTS IN ISOLATED AND BLOOD- 
PERFUSED FELINE HEARTS 
In an experimental model of isolated and blood-per- 
fused feline hearts made globally ischemic for 60 minutes 
and followed by reperfusion for 60 minutes, infusion of 
amlodipine before the induction of global ischemia signif- 
icantly (p <O.OS) curtailed the development of ischemic 
contracture. There was minimal or no increase in left 
ventricular end-diastolic pressure in the amlodipine- 
treated hearts, compared with a significant progressive 
increase in left ventricular end-diastolic pressure in sa- 
line-treated control animals. 
Although no ventricular fibrillation occurred during 
the ischemic period, all hearts fibrillated immediately 
when reperfused. A better spontaneous recovery of sino- 
atria1 rhythm (85.7%) was observed in the amlodipine- 
treated hearts than in the saline-treated hearts (54.5%), myocardial ischemia and 15 minutes before the onset of 
but the difference was not statistically significant. reperfusion. 
Significant (p <0.05) decreases in left ventricular The overall area at risk (measured by the Evans-blue 
compliance were observed in the isolated hearts of both dye technique) for both amlodipine-treated and control 
groups. However, the shift to the left in pressure-volume dogs was 40.2 f 4.9%. Amlodipine achieved a 24.8% 
curves of the amlodipine-treated group was significantly reduction (p (0.025) in ultimate infarct size (measured 
(p <0.0.5) less than that in the placebo group. by the triphenyltetrazolium chloride technique), deter- 
Pretreatment with amlodipine attenuated the declines mined as a percentage of the area at risk (Fig. 5). A 
in left ventricular developed pressure (Fig. 1) and left significant difference (p <0.05) was also observed when 
ventricular +dP/dt (Fig. 2) observed in all hearts after the infarct size was expressed as a percent of the left 
ischemia and reperfusion. Thus, amlodipine protected the ventricle: 18.6 f 1.5% for the saline group and 13.6 Z!Z 
reperfused ischemic heart from depression of myocardial 1.6% for the amlodipine group. There were no significant 
contractility. Coronary blood flow increased 30% (p = differences in hemodynamics between the 2 groups. 
0.021) in the saline-treated hearts and 127% (p = 0.002) The calcium concentration of tissue within the area of 
in the amlodipine-treated hearts (Fig. 3). Despite the risk was greater than that of myocardial tissue from the 
obviously greater increase in the amlodipine group, the nonischemic region (Fig. 6). Amlodipine significantly de- 
differences between treatments were short of statistical creased the elevation of calcium in the noninfarcted tissue 
significance. within the area at risk and somewhat diminished calcium 
Amlodipine significantly reduced the loss of intracel- in the center of the infarcted zone. 
lular potassium and the accumulation of calcium during 
reperfusion (Fig. 4). These results support the conclusion ISCUSSION 
that this agent preserves both systolic and diastolic func- These experiments in isolated and blood-perfused fe- 
tions of the isolated ischemic and reperfused heart. line hearts show that amlodipine given before the onset of 
global ischemia preserves myocardial function. Similar 
NEARS CANINE’ cardioprotection has been demonstrated with other calci- 
Is amlodipine capable of actually reducing anatomic um antagonists.22-24 In addition, we demonstrated in the 
myocardial infarct size? To answer this question, anes- intact canine heart that amlodipine given after the onset 
thetized dogs were subjected to 90 minutes of coronary of ischemia 15 minutes before reperfusion reduces the 
artery occlusion followed by 6 hours of reperfusion extent of myocardial necrosis after 90 minutes of regional 
through a critical stenosis. The dogs were assigned ran- ischemia. Calcium antagonists,6J5J7 administered before 
domly to treatment with either amlodipine (150 hg/kg the onset of ischemia, have been shown to reduce infarct 
dissolved in 20 ml saline) or with saline alone. Treatment size in models of permanent occlusion and ischemia-re- 
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FIGURE 1. Ventricular function curves of the isolated and URE 2. Left ventricular +dP/dt of the cat blood-perfused, 
blood-perfused feline heart. tiEM = standard error of the isolated heart. SEM = standard error of the mean. (Redrawn, 
mean. (Redrawn, with permission, from Hoff et al.*“) with permission, from Hoff et aL2*) 
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The isolated and blood-perfused feline heart allowed 
an assessment of the effects of amlodipine on myocardial 
performance and electrolyte balance independent of he- 
modynamic and central nervous system variations. In 
addition, this model had the advantage of assuring global 
ischemia and eliminating the possible mechanism of coro- 
nary steaLz5 
Experiments in isolated myocytes have shown that 
pretreatment with the calcium antagonists nifedipine and 
diltiazem did not prevent hypercontracture, but pretreat- 
ment with the nonspecific agents lidoflazine and flunara- 
zine did afford protection. 26 These findings suggest a 
possible intracellular action of calcium regulation. Spere- 
p - 0.002 
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lakis*’ suggested that the increase in calciumi during 
ischemia might be a consequence of failure of the meta- 
bolic processes to extract free calcium from the cell, 
Dhalla et al28 demonstrated an inhibition of earcoplasmic 
reticular calcium adenosine triphosphatase uptake and 
sodium-calcium exchange mechanism8 during anoxia 
and ischemia. It it likely that calcium has more than 1 
route of entry during reperfusion. The dihydropyridines 
are believed to bind eelectively to sites directly within the 
ion channel,29 which may impart some undetermined ac- 
tion independent of ion fluxa30 Thk action may provide an 
explanation for the observation that specific calcium an- 
tagonists can postpone, but not abolish, the reperfusion- 
induced accumulation of calcium that leads to cell death. 
Our data from the isolated cardiac preparation sug- 
gest that amlodipine limits the alterations in electrolyte 
homeostasis, namely, the increases in total tissue calcium 
and sodium and the decrease in potassium associated 
with ischemia and reperfusion. The increase we observed 
in tissue calcium is compatible with the rapid accumula- 
tion of calcium associated with reperfusion. This cannot 
occur solely through activation of the slow channels31 
Various mechanisms have been proposed for the gradual 
deterioration of the membrane during ischemia. These 
include activation of phospholipases3* or accumulation of 
lipids33 or oxygen free radical8,34 which remove the physi- 
cal barriers allowing the free diffusion of calcium down 
its concentration gradient at reperfusion. The decline in 
total calcium after pretreatment with amlodipine may 
result from an inhibition of the events that trigger mem- 
brane damage during ischemia; the metabolic and struc- 
tural changes that normally provide the substrate for 
reperfusion injury (calcium overload) may be eliminated. 
emia. By suppressing the induction of myocyte hypercon- 
Amlodipine inhibited the increase in left ventricular 
end-diastolic pressure throughout the 60 minutes of isch- 
of ischemia plus reperfusion. (Redrawn, with permission, from 
Hoff et al.*‘) 
flGURE 3. Coronary blood flow before and after 60 minutes 
0 
n=6 n-6 n=6 n=6 
0 Saline-treated group, donor heart 
II Saline-treated group, ischemia-repetfused 
m Amlodipine-treated group, donor heart 
m Amlodipine-treated group, ischemia-reperfused 
FIGURE 4. Myocardial calcium content 
(runollg, dry weight). *p 10.05: donor 
heart vs ischemia-reporlused heart. tp 
50.05: saline-treated group VI amlodi- 
pine-treated group. (Data from Hoff et 
al.*‘) 
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tracture, amlodipine may obviate additional mechanical 
disruption and chemical degradation of the sarcolemmal 
membrane and render the cells less susceptible to calcium 
overload during reperfusion. 
The intact canine heart model provided the opportuni- 
ty to assess drug responses under more physiologic condi- 
tions, The ability of amlodipine to reduce the extent of 
myocardial necrosis that occurs during the late stage of 
ischemia and reperfusion was assessed in this model. We 
previously demonstrated that reproducible regional myo- 
cardial necrosis can be induced in the canine heart after 
temporary coronary occlusion followed by reperfu- 
sion.15J9Jo With physiologic hemodynamic and central 
nervous system responses maintained, it was possible to 
monitor drug-related changes in systemic arterial blood 
pressure, heart rate, coronary blood flow and myocardial 
oxygen consumption. 
First-generation calcium antagonists administered 
before the onset of coronary occlusion in intact animal 
hearts have been shown to reduce infarct size and im- 
prove cardiac function. ‘5~~ By directly inhibiting neutro- 
phi1 activation, these agents may help to reduce the uiti- 
mate extent of damage. 36,37 However, they have not been 
shown to be effective if administered at the time of perfu- 
sion30 Solutions containing low concentrations of calci- 
um or acidic reperfusate cannot prevent cellular damage, 
although they can delay its onset.31 
Much of the damage associated with reperfusion is 
thought to occur within minutes of the resumption of 
flo~.~~ Total cellular calcium concentration remains con- 
stant during ischemia and increases precipitously during 
reperfusion.39 The rapid loss of sarcolemmal membrane 
integrity associated with restoration of flow and derange- 
ment of homeostatic mechanisms most likely prevent cal- 
cium antagonists from improving cardiac function and 
reducing infarct size when administered during reperfu- 
sion only. Ischemia primes the cells for destruction 
through activation of proteases, oxygen free radicals and 
calcium adenosine triphosphatase.‘1,28 During reperfu- 
sion, the sarcolemma is disrupted, a phenomenon that is 
FIGURE 5. Region of tissue representing 
the area at risk as a percentage of the left 
ventricle and myocardial infarct size taken 
as a fraction of the area at risk. NS = not 
significant. (Redrawn, with permission, 
from Hoff et aLzl) 
E 6. T3sme cakiim @a*+) cencen- 
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not manifest during ischemia alone, although the cell 
membrane has altered permeability.31140*41 Hence, calci- 
um can move freely into the cytoplasmic space during 
reperfusion. Calcium influx may be one of the final com- 
mon pathways leading to myocardial dysfunction and 
necrosis. 
Amlodipine administered 15 minutes before the be- 
ginning of reperfusion reduced infarct size and intracellu- 
lar calcium concentrations in the noninfarcted tissue in 
the region at risk, Neither verapamil nor diltiazem ad- 
ministered at the time of reperfusion exhibited a cardio- 
protective effect, although nifedipine and the calmodulin 
antagonist, W-7, were effective when administered at 
reperfusion or before ischemia.30 Thus, calcium antago- 
nists may have different effects on the sarcolemmal mem- 
brane, with the second-generation calcium antagonist, 
amlodipine, showing a greater ability to prevent sarco- 
lemma1 disruption on reperfusion. Additionally, nifedi- 
pine may provide an intracellular action similar to that of 
W-7 on calmodulin.42 
The results of our experiments suggest hat the reduc- 
tion in myocardial infarct size was independent of altered 
hemodynamics, which did not show differences between 
treated and control dogs. These results agree with our 
Andings in the isolated hearts and suggest hat amlodi- 
pine’s mechanism of action is not due simply to altering 
heart rate or blood pressure. 
Myocardial Infarct Size 
(6 Hours Occlusion/24 Hours Reperhsion) 
n=6 
PEG-SOD N-SOD PEG-ALB SALINE 
PfGURE 7. Reduction In myocardial infarct size in the canine 
heart subjected to 6 hours of reglonal ischemia followed by 34 
hours of reperfusion. Salvage of myocardlal tissue Is achieved 
with the polyethylene conjugated form of superoxlde dtsmu- 
tare (PEG-SOD) in contrast to the native enzyme (SOD), which 
does not result in a reductton in irreversible myocardial Injury. 
PEGGOD has a pharmacologic half-life >30 hours as com- 
pared to the lo-minute half-life of native SOD. The co&rued 
generation of oxygen free radicals in the postischemlc heart 
may account for the progressive extension of myocyte tnjury. 
An agent that wtll provide protection against the damage as- 
sociated with reperfusion must possess a pharmacoklnetic 
profk that wilt extend into the period during which lrrevers- 
tble cell injury can occur. PEG-ALB = polyethylene conjugated 
form of ajbumtn. 
Excessive influx of calcium occurs almost exclusively 
during reperfusion and cannot be due entirely to in- 
creased conductance through the calcium channe1.31g43 
The administration of amlodipine 15 minutes before re- 
perfusion achieved a reduction of infarct size typical of 
hearts treated before ischemia, but distinct from those 
treated only during reperfusion. Amlodipine adminis- 
tered prophylactically during late ischemia may provide 
enough protection to sustain the sarcolemma nd calcium 
homeostasis mechanisms during reperfusion. Lowered 
accumulation of tissue calcium compared with control 
animals indicates that amlodipine may directly protect 
the myocardium during ischemia, and the effect may 
persist into the reperfusion phase either through mem- 
brane stabilization or intracellular mechanisms. More- 
over, amlodipine may inhibit activation of leukocytes that 
would curtail enzymatic and oxidative damage conse- 
quent to ischemia and reperfusion36J7 
The evidence for generation of oxygen free radicals 
during myocardial reperfusion would suggest hat super- 
oxide dismutase (SOD) and other free radical scavengers 
might alter the extent of myocardial injury. A number of 
studies from our laboratory as well as those of others have 
supported the hypothesis that free radical scavengers 
have a protective action against the extension of myocar- 
dial injury related to reperfusion.44 Chi et a14j have pre- 
sented evidence for the sustained presence of oxygen radi- 
cal scavenger activity as being essential for the prevention 
of infarct extension rather than delay of necrosis after 
reperfusion. Figure 7 presents a summary of the results of 
a comparison made between the native form of SOD 
(with a half-life of 10 minutes) and the polyethylene 
conjugated form of the enzyme (PEG-SOD), which has a 
half-life in excess of 30 hours. Only the PEG-SOD was 
effective in reducing ultimate infarct size when assessed 
24 hours after reperfusion. The interpretation of the re- 
sults conforms to that cited earlier46 in which there was a 
direct demonstration of sustained oxyradical generation 
in the postischemic heart. Additional studies are needed 
to determine whether there is a link between the reduc- 
tion in infarct size as achieved with calcium antagonists 
and that obtained with oxygen radical scavengers. Do 
oxyradicals impair the removal of calcium from the myo- 
cardial cell? Do calcium antagonists provide their benefi- 
cial effect by interfering with ion movement in the slow 
calcium channel? Do calcium antagonists affect cell-to- 
cell interactions that are known to participate in reperfu- 
sion injury such as the events involving neutrophil-medi- 
ated cell injury? Substantial investigative efforts must 
now be directed toward resolving some of the questions 
regarding the manner in which several diverse pharmaco- 
logic agents can achieve a similar outcome with respect o 
reducing myocardial reperfusion injury. 
The pharmacokinetic profile of amlodipine may prove 
valuable in protection of the postischemic heart. A single 
intravenous dose of 10 mg resulted in an absolute bio- 
availability of 64% and a calculated half-life of 34 hours. 
Similar values were obtained after oral administration of 
the drug. The pharmacokinetic data with amlodipine 
contrast with the results of similar studies using most 
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other dihydro~yridine and ~o~dihydro~yridi~e calcium 
antagonists. Most dihydropyr~d~~e calcium antagonists 
have an elimination half-life LX’+ about 3 to 10 hours. The 
~ond~hydropyridi~e calcium antagonists show an elimi- 
nation half-life of 3 to 6 hours, The prolonged 
of oxyradieals in the ~ostis~hemi~ heart ma 
affect calcium ~Qmeostaa~s, Zt is intriguing to suspect, 
therefore, that amlodi ’ y Serve to modulate the 
otherwise unfavorable in intracellular calcium 
and thereby reduce the of irreversible cell injury 
associated with reperfusion. The prolonged pharmacolo 
ic action of amlodipine would provide the extended dura- 
on necessary to reduce the extent of the 
in the postischemic heart. 
There is a growing body af evidence ~~d~~at~ng the 
participation of reactive oxygen metabolites (superoxide 
anion, hydrogen peroxide, hydroxyl anion) as contribu- 
tors to the tissue damage associated with reperfusion.44147 
The exact mechanism by which reactive oxygen species 
produce alterations in cardiac function and myocyte via- 
bility is not known. Recent studies have suggested that 
the sarcolemmal membrane is altered by exposure to 
superoxide anion, and this may result in depressing the 
calcium-pump mechanism that facilitates efflux of the 
divalent ion from the myocardial cel1.48l49 The inhibition 
of sarcolemmal calcium-pump activities by superoxide 
anion was decreased by the addition of dithiothreitol or 
cysteine in a dose-dependent manner.4g Heart sarcolem- 
ma1 sulfhydryl groups were depressed by superoxide an- 
ion, hydrogen peroxide and hydroxyl anion. SOD, cata- 
lase and D-mannitol showed protective effects on the sulf- 
hydryl group depression by the several reactive oxygen 
metabolites. The increase in intracellular calcium ob- 
served to occur in myocardial ischemia/reperfusion inju- 
ry may be a manifestation of an oxygen free radical- 
mediated depression of the mechanism(s) responsible for 
removal of cytosolic free calcium. Spin trapping tech- 
niques have been used to demonstrate the formation of 
free radicals during regional myocardial ischemia. Evi- 
dence has been provided to indicate the presence of oxy- 
gen- and carbon-centered radical adducts in the coronary 
venous blood draining from the ischemic bed on reperfu- 
sion of the ischemic heart50 Studies in the canine heart 
subjected to 98 minutes of regional ischemia followed by 
r6~erfusion have demonstrated the sustained generation 
of oxyradicals 1 to 3 hours after the restoration of blood 
flow. There was an associated progressive increase in 
infarct size supporting the view that a chain reaction of 
oxyradicals contributes to the propagation of myocardial 
cell damage in the postischemic heart,46 
In conclusion, experimental data demonstrate that 
a~~lodip~n~, a second-generation long-acting dihydropyr- 
idine with somewhat unique binding properties, is effec- 
tive in prese~~~g myocardial contractile function and 
attenuating calcium accumulation after 60 minutes of 
ischemia and reperfusion when administered before the 
onset of ischemia. It also limits ultimate infarct size when 
administered 15 minutes before the beginning of reperfu- 
sion and after 15 minutes of regional ischemia. The pro- 
tective effect was associated with reduced accumulation 
of calcium in noninf~rcted tissue in the area at risk. 
data suggest that amlodipine may have utility as a cardio- 
protective agent to pre function and cell 
viability during myocar and reperfusion. 
Comparable data wi he reduction in in- 
farct size and the preservation of contractile function 
after brief periods of global or regional ischemia have 
been obtained with agents know enge oxygen free 
radicals, There is evidence to that oxyradicals 
may influence the mechanisms that control calcium accu- 
mulation in the myocardial cell and thereby lead to irre- 
versible cell injury or an alteration in contractile function. 
It is intriguing to speculate that a common mechanism 
that subjects the myocyte to permanent damage may be 
operative. Am~od~pine, with its interesting pharmacologic 
and ~harmacoki~etic profiles, may provide a means of 
modulating the myocardial injury in the postis~hemi~ 
heart. 
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